SCHEMBL4935801

SCHEMBL4935801

COc1ccc(Cn2nc(N)c3cc(OC)cnc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PDE8B O95263 2/20 0.42
PDE5A O76074 1/20 0.42
PDE1B Q01064 6/20 0.42
ALOX15 P16050 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
NPBWR1 P48145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29872928 0.90 KDM4E (0.43) CNR1CNR2ALDH1A1LMNAMAPT
SCHEMBL23069193 0.89 CNR1 (0.44) CNR1CNR2ALDH1A1LMNAMAPT
SCHEMBL15999430 0.89 PDE1B (0.54) CNR1CNR2ALDH1A1LMNAMAPT
SCHEMBL29872970 0.84 MAPT (0.49) CNR1CNR2LMNAMAPTSMN1; SMN2
SCHEMBL19798298 0.82 L3MBTL1 (0.52) CNR1CNR2ALDH1A1LMNAMAPT
SCHEMBL29872929 0.80 NPBWR1 (0.43) CNR1CNR2ALDH1A1LMNAMAPT
SCHEMBL4787267 0.80 CNR1 (0.52) CNR1CNR2ALDH1A1MAPTPDE8B
SCHEMBL1593023 0.80 CNR1 (0.47) CNR1CNR2ALDH1A1LMNAMAPT
SCHEMBL1593160 0.79 MAPT (0.43) CNR1CNR2ALDH1A1LMNAMAPT
SCHEMBL1593142 0.77 CNR1 (0.47) CNR1CNR2ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC BUCK INST RES AGING (US) 2024-07-04 US disclosed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 CNR1 247/4885CNR2 89/4885ALDH1A1 752/4885
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC DAGLA, DAGLB, MGLL CNR1 3044/4885CNR2 2756/4885ALDH1A1 978/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG CNR1 890/4885CNR2 613/4885ALDH1A1 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.